Search

everythinglearnresearchcommunity

for

Search:↓

Early treatment and lifestyle changes are important for managing PCOS in young people to prevent long-term health issues.

A woman's severe hormone imbalance after menopause led to finding a rare ovarian tumor, treated by surgery.

Testosterone therapy can improve sexual desire and function in postmenopausal women but should be used cautiously and not based solely on testosterone levels.

Metformin helps with menstrual cycles and insulin levels in PCOS but is less effective for hair growth, diabetes prevention, and weight loss, and may improve fertility and reduce diabetes risk.

Most cases of high male hormone levels in women are due to polycystic ovary syndrome.

Too much male hormone is the main cause of Polycystic Ovary Syndrome.

Obesity affects skin health, causing conditions like acanthosis nigricans and may require different treatment approaches.

Testosterone therapy seems safe for postmenopausal women for a few years, but more research is needed for long-term effects.

Birth control pills increase the risk of blood clots, especially within the first year and with certain types.

Women with PCOS have fewer activated T cells in their ovarian follicles, which might affect fertility.

The guideline suggests using specific criteria to diagnose PCOS, recommends various treatments for its symptoms, and advises screening for related health issues.

Hormonal changes and psychological issues can cause sexual dysfunction in postmenopausal women. Behavioral therapy is recommended first, with hormone replacement helping some symptoms but not libido. Testosterone can improve libido, but its effects on overall sexual function are unclear. Emotional and relationship issues should be addressed before using medication, and the benefits and risks of testosterone supplementation should be considered.

The Li-Pa/Ca and Do/Ca chemotherapy regimens for serous ovarian cancer showed better short-term and long-term results than the Pa/Ca regimen.

PCOS affects a similar percentage of Black and White women in the Southeastern United States.

Cyproterone acetate is the preferred treatment for women's hyperandrogenism when estrogen/progestogen use is safe.

Newer low-dose oral contraceptives with less androgenic effects improve patient compliance.

Platelet-derived bio-products help in wound healing and tissue regeneration but lack standardized methods, and their use in medicine is growing.

The combination therapy improved PCOS symptoms in both obese and non-obese women, with weight loss in the obese group.

The IRS-2 Asp/Asp genotype may increase the risk of PCOS in Chinese women, especially if they are not obese.

Chemotherapy often causes skin, nail, and hair side effects, significantly impacting quality of life.

Mesenchymal stromal cell therapies show promise for treating various diseases but need more research and standardization.

Hormonal changes and conditions like polycystic ovarian syndrome are major causes of adult acne in women, with varying prevalence among different ethnicities.

Medications for PCOS don't seem to raise heart disease risk.

Brown Adipose Tissue (BAT) could potentially treat Polycystic Ovary Syndrome (PCOS) by controlling energy balance and lipid homeostasis, but more human research is needed.

All women with Polycystic Ovary Syndrome (PCOS) in a study had at least one skin disorder, with the most common being excessive hair growth, acne, dark skin patches, hair loss, and oily skin.

The study concluded that both anti-Mullerian hormone and LH/FSH ratio are higher in women with PCOS and combining these markers with BMI could improve diagnosis accuracy.

The document concludes that proper diagnosis and combined treatments are key for hirsutism management, and weight loss may help overweight patients.

Testosterone therapy may slightly increase sexual desire in women with HSDD but lacks broad recommendation due to safety concerns and limited approval.

The document concludes that effectively managing PCOS requires a multifaceted approach.